{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:00:10Z","timestamp":1784700010158,"version":"3.55.0"},"reference-count":118,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Acute myeloid leukemia (AML) comprises 15\u221220% of pediatric leukemia and 35% of adult leukemia cases, requiring insights into prognostic factors of this disease to be an important aspect of diagnosis and treatment. A mutational profile of patients with AML is a crucial predictor of their outcome. Discernment of present mutations, co-mutation combinations, and variations in the mutations in a single gene requires proper research and analysis to determine their impact on a patient\u2019s prognosis. Common and infrequent mutations are continuously investigated and analyzed in different patient cohorts, bringing new insights that lead to changes in classifications, treatments, and diagnoses. For instance, mutations in NPM1, FLT3, and DNMT3A, three frequent driver mutations, have high incident rates with differing prognoses and treatments in pediatric and adult patients. AML patients with MECOM face particularly dire outcomes, as well as those with ASXL1 and TP53, making their mutational analysis crucial for review in developing a prognosis.<\/jats:p>","DOI":"10.3390\/diagnostics15192537","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:51:13Z","timestamp":1759935073000},"page":"2537","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Mutational Landscape in Acute Myeloid Leukemia: Overview and Prognostic Impacts"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3642-5008","authenticated-orcid":false,"given":"Jeff","family":"Chen","sequence":"first","affiliation":[{"name":"The International Circle of Genetic Studies Project, Stony Brook, NY 11794, USA"},{"name":"Department of Biology, Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6808-2434","authenticated-orcid":false,"given":"Fares","family":"Hassan","sequence":"additional","affiliation":[{"name":"The International Circle of Genetic Studies Project, Stony Brook, NY 11794, USA"},{"name":"Department of Biology, Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5339-5347","authenticated-orcid":false,"given":"Carlos A.","family":"Tirado","sequence":"additional","affiliation":[{"name":"The International Circle of Genetic Studies Project, Stony Brook, NY 11794, USA"},{"name":"Department of Biology, Stony Brook University, Stony Brook, NY 11794, USA"},{"name":"Department of Pathology, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"ref_1","first-page":"12","article-title":"Acute Myeloid Leukemia: Novel Mutations and Their Clinical Implications","volume":"13","author":"Makkar","year":"2023","journal-title":"Am. J. Blood Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic Risk Classification for Adults with AML Receiving Less-Intensive Therapies: The 2024 ELN Recommendations","volume":"144","author":"DiNardo","year":"2024","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/jcm4010127","article-title":"Pediatric AML: From Biology to Clinical Management","volume":"4","author":"Zwaan","year":"2015","journal-title":"J. Clin. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The Molecular Landscape of Pediatric Acute Myeloid Leukemia Reveals Recurrent Structural Alterations and Age-Specific Mutational Interactions","volume":"24","author":"Bolouri","year":"2017","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/1878-0261.12899","article-title":"Insights into the Molecular Profiles of Adult and Paediatric Acute Myeloid Leukaemia","volume":"15","author":"Aung","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: Prognostic and Therapeutic Implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","article-title":"Current Status and Future Perspectives in Targeted Therapy of NPM1-Mutated AML","volume":"36","author":"Ranieri","year":"2022","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-Mutated Acute Myeloid Leukemia: From Bench to Bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/archdischild-2013-304340","article-title":"What Is next Generation Sequencing?","volume":"98","author":"Behjati","year":"2013","journal-title":"Arch. Dis. Child. - Educ. Pract. Ed."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1182\/bloodadvances.2022007583","article-title":"Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation","volume":"7","author":"Levy","year":"2023","journal-title":"Blood Adv."},{"key":"ref_12","unstructured":"(2025, April 02). Bionano Optical Genome Mapping. Available online: https:\/\/www.mdanderson.org\/research\/research-resources\/core-facilities\/advanced-technology-genomics-core\/services-and-fees\/bionano-optical-genome-mapping.html."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Han Yu, P., Yan Zhang, Z., Yuan Kang, Y., Huang, P., Yang, C., and Naranmandura, H. (2025). Acute Myeloid Leukemia with T(8;21) Translocation: Molecular Pathogenesis, Potential Therapeutics and Future Directions. Biochem. Pharmacol., 233.","DOI":"10.1016\/j.bcp.2025.116774"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1038\/s41467-022-31489-9","article-title":"Poor Outcome of Pediatric Patients with Acute Myeloid Leukemia Harboring High FLT3\/ITD Allelic Ratios","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Tang, Z., Wang, W., Yang, S., El Achi, H., Fang, H., Nahmod, K.A., Toruner, G.A., Xu, J., Thakral, B., and Ayoub, E. (2023). 3q26.2\/MECOM Rearrangements by Pericentric Inv(3): Diagnostic Challenges and Clinicopathologic Features. Cancers, 15.","DOI":"10.3390\/cancers15020458"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/pbc.23179","article-title":"Leukemic Mutations in the Methylation-Associated Genes DNMT3A and IDH2 Are Rare Events in Pediatric AML: A Report from the Children\u2019s Oncology Group","volume":"57","author":"Ho","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"13182","DOI":"10.1002\/cam4.6005","article-title":"Clinical Characteristics and Prognosis Analysis of Patients with de Novo ASXL1-Mutated AML Treated with the C-HUNAN-AML-15 Protocol: A Multicenter Study by the South China Pediatric AML Collaborative Group","volume":"12","author":"Zeng","year":"2023","journal-title":"Cancer Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"106910","DOI":"10.1016\/j.leukres.2022.106910","article-title":"Prognostic Value of ASXL1 Mutations in Acute Myeloid Leukemia: A Meta-Analysis","volume":"120","author":"Lipilkin","year":"2022","journal-title":"Leuk. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40164-023-00449-4","article-title":"Identification of a Novel NPM1 Mutation in Acute Myeloid Leukemia","volume":"12","author":"Yao","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.3324\/haematol.2014.117796","article-title":"BCOR and BCORL1 Mutations in Pediatric Acute Myeloid Leukemia","volume":"100","author":"Hermkens","year":"2015","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood.2021010958","article-title":"BCOR Gene Alterations in Hematologic Diseases","volume":"138","author":"Sportoletti","year":"2021","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MPH.0000000000002840","article-title":"Acute Myeloid Leukemia and Next-Generation Sequencing Panels for Diagnosis: A Comprehensive Review","volume":"46","author":"Chaudhary","year":"2024","journal-title":"J. Pediatr. Hematol.\/Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Leisch, M., Jansko, B., Zaborsky, N., Greil, R., and Pleyer, L. (2019). Next Generation Sequencing in AML-on the Way to Becoming a New Standard for Treatment Initiation and\/or Modulation?. Cancers, 11.","DOI":"10.3390\/cancers11020252"},{"key":"ref_24","unstructured":"(2025, May 14). Illumina AmpliSeq for Illumina Myeloid Panel. Available online: https:\/\/www.illumina.com\/products\/by-type\/sequencing-kits\/library-prep-kits\/ampliseq-myeloid-panel.html?."},{"key":"ref_25","unstructured":"(2025, May 14). QIAGEN QIAseq Targeted DNA Human Myeloid Neoplasms Panel|GeneGlobe. Available online: https:\/\/geneglobe.qiagen.com\/us\/product-groups\/qiaseq-targeted-dna-panels\/DHS-003Z?."},{"key":"ref_26","unstructured":"(2025, May 14). Quest Diagnostics LeukoVantage Myeloid Neoplasm Mutation Panels|Quest Diagnostics. Available online: https:\/\/www.questdiagnostics.com\/healthcare-professionals\/clinical-education-center\/faq\/faq208?."},{"key":"ref_27","unstructured":"(2025, May 15). OGT SureSeq MyPanel Custom AML NGS Panel|OGT. Available online: https:\/\/www.ogt.com\/products\/product-search\/sureseq-mypanel-custom-aml-next-generation-sequencing-ngs-panel\/."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cancergen.2021.12.009","article-title":"Newly Designed Breakapart FISH Probe Helps to Identify Cases with True MECOM Rearrangement in Myeloid Malignancies","volume":"262\u2013263","author":"Zhao","year":"2022","journal-title":"Cancer Genet."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Schrauwen, I., Rajendran, Y., Acharya, A., \u00d6hman, S., Arvio, M., Paetau, R., Siren, A., Avela, K., Granvik, J., and Leal, S.M. (2024). Optical Genome Mapping Unveils Hidden Structural Variants in Neurodevelopmental Disorders. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-62009-y"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/clinchem\/hvae173","article-title":"Innovations in Short-Read Sequencing Technologies and Their Applications to Clinical Genomics","volume":"71","author":"Polonis","year":"2025","journal-title":"Clin. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ran, W.-J., Xu, L.-P., Zhang, X.-H., Chang, Y.-J., Mo, X.-D., Sun, Y.-Q., Huang, X.-J., and Wang, Y. (2025). Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32060294"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13039-025-00718-3","article-title":"What the VAF? A Guide to the Interpretation of Variant Allele Fraction, Percent Mosaicism, and Copy Number in Cancer","volume":"18","author":"Smith","year":"2025","journal-title":"Mol. Cytogenet."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zarka, J., Short, N.J., Kanagal-Shamanna, R., and Issa, G.C. (2020). Nucleophosmin 1 Mutations in Acute Myeloid Leukemia. Genes, 11.","DOI":"10.3390\/genes11060649"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"McGowan-Jordan, J., Hastings, R.J., and Moore, S. (2020). ISCN 2020: An International System for Human Cytogenomic Nomenclature (2020). Reprint of: Cytogenetic and Genome Research 2020, Vol. 160, No. 7-8, S Karger AG.","DOI":"10.1159\/isbn.978-3-318-06867-2"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1097\/HS9.0000000000000326","article-title":"Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation","volume":"4","author":"Jentzsch","year":"2020","journal-title":"HemaSphere"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wang, R., Xu, P., Chang, L.-L., Zhang, S.-Z., and Zhu, H.-H. (2022). Targeted Therapy in NPM1-Mutated AML: Knowns and Unknowns. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.972606"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood.2024024074","article-title":"Transplant in AML: Just Follow the NPM1 Guide!","volume":"143","year":"2024","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2022008316","article-title":"Clinical Outcomes Associated with NPM1 Mutations in Patients with Relapsed or Refractory AML","volume":"7","author":"Issa","year":"2023","journal-title":"Blood Adv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0268-7","article-title":"Nucleophosmin Mutations Confer an Independent Favorable Prognostic Impact in 869 Pediatric Patients with Acute Myeloid Leukemia","volume":"10","author":"Xu","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Dhillon, V., Khan, A.M., Justin, J., Reddy, S.N., Aly, M.M., Kewan, T., Bahaj, W., Gurnari, C., Visconte, V., and Carr, D. (2025). Comprehensive Age-Stratified Impact of NPM1 Mutation in Acute Myeloid Leukemia: A Real-World Experience. Cancers, 17.","DOI":"10.3390\/cancers17061020"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.3324\/haematol.2018.189886","article-title":"NPM1 Mutation Is Not Associated with Prolonged Complete Remission in Acute Myeloid Leukemia Patients Treated with Hypomethylating Agents","volume":"103","author":"Prata","year":"2018","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s12185-024-03835-8","article-title":"Recent Advances in AML with Mutated NPM1","volume":"120","author":"Ishikawa","year":"2024","journal-title":"Int. J. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1182\/bloodadvances.2020004136","article-title":"Prognostic Impact of DNMT3A Mutation in Acute Myeloid Leukemia with Mutated NPM1","volume":"6","author":"Bataller","year":"2022","journal-title":"Blood Adv."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Borlenghi, E., Cattaneo, C., Bertoli, D., Cerqui, E., Archetti, S., Passi, A., Oberti, M., Zollner, T., Giupponi, C., and Pagani, C. (2022). Prognostic Relevance of NPM1 and FLT3 Mutations in Acute Myeloid Leukaemia, Longterm Follow-up-A Single Center Experience. Cancers, 14.","DOI":"10.3390\/cancers14194716"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Greiner, J., Mohamed, E., Fletcher, D.M., Schuler, P.J., Schrezenmeier, H., G\u00f6tz, M., and Guinn, B. (2024). Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia. Cancers, 16.","DOI":"10.20944\/preprints202406.1388.v1"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/hematolrep16020024","article-title":"A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia","volume":"16","author":"Candoni","year":"2024","journal-title":"Hematol. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-024-02438-w","article-title":"NPM1-Fusion Proteins Promote Myeloid Leukemogenesis through XPO1-Dependent HOX Activation","volume":"39","author":"Shimosato","year":"2024","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood-2024-206075","article-title":"Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia","volume":"144","author":"Dhiman","year":"2024","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.4081\/oncol.2012.e8","article-title":"An Overview on the Role of FLT3-Tyrosine Kinase Receptor in Acute Myeloid Leukemia: Biology and Treatment","volume":"6","author":"Grafone","year":"2012","journal-title":"Oncol. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-8722-4-13","article-title":"Downstream Molecular Pathways of FLT3 in the Pathogenesis of Acute Myeloid Leukemia: Biology and Therapeutic Implications","volume":"4","author":"Takahashi","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"Differential Impact of Allelic Ratio and Insertion Site in FLT3-ITD-Positive AML with Respect to Allogeneic Transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","article-title":"Prognostic Relevance of FLT3-TKD Mutations in AML: The Combination Matters--an Analysis of 3082 Patients","volume":"111","author":"Bacher","year":"2008","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1182\/bloodadvances.2023009748","article-title":"FLT3-ITD Does Not Predict Inferior Prognosis in Acute Myeloid Leukemia Patients Aged \u226560 Years","volume":"7","author":"Shimony","year":"2023","journal-title":"Blood Adv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Na\u00efve Acute Myeloid Leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","article-title":"Cytogenetics and Gene Mutations Influence Survival in Older Patients with Acute Myeloid Leukemia Treated with Azacitidine or Conventional Care","volume":"32","author":"Dolnik","year":"2018","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Rataj, J., Gorecki, L., Muthna, D., Sorf, A., Krystof, V., Klener, P., Ceckova, M., Rezacova, M., and Korabecny, J. (2024). Targeting FMS-like Tyrosine Kinase 3 (FLT3) in Acute Myeloid Leukemia: Novel Molecular Approaches and Therapeutic Challenges. Biomed. Pharmacother., 182.","DOI":"10.1016\/j.biopha.2024.117788"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s43042-024-00570-x","article-title":"Characteristics of DNMT3A Mutation in Acute Myeloid Leukemia and Its Prognostic Implication","volume":"25","author":"Khattab","year":"2024","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5045\/br.2020.55.1.17","article-title":"Characteristics of DNMT3A Mutations in Acute Myeloid Leukemia","volume":"55","author":"Park","year":"2020","journal-title":"Blood Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood.2019003339","article-title":"Co-Occurrence of DNMT3A, NPM1, FLT3 Mutations Identifies a Subset of Acute Myeloid Leukemia with Adverse Prognosis","volume":"135","author":"Bezerra","year":"2020","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Chaudry, S.F., and Chevassut, T.J.T. (2017). Epigenetic Guardian: A Review of the DNA Methyltransferase DNMT3A in Acute Myeloid Leukaemia and Clonal Haematopoiesis. Biomed Res. Int., 2017.","DOI":"10.1155\/2017\/5473197"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/cas.15720","article-title":"Mutational Analysis of DNMT3A Improves the Prognostic Stratification of Patients with Acute Myeloid Leukemia","volume":"114","author":"Wakita","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/blood-2017-04-777029","article-title":"DNMT3A and TET2 Dominate Clonal Hematopoiesis and Demonstrate Benign Phenotypes and Different Genetic Predispositions","volume":"130","author":"Buscarlet","year":"2017","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.2023022222","article-title":"Causes and Consequences of Clonal Hematopoiesis","volume":"142","author":"Weeks","year":"2023","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3324\/haematol.2023.283510","article-title":"Exclusion of Persistent Mutations in Splicing Factor Genes and Isocitrate Dehydrogenase 2 Improves the Prognostic Power of Molecular Measurable Residual Disease Assessment in Acute Myeloid Leukemia","volume":"109","author":"Murphy","year":"2023","journal-title":"Haematologica"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_70","first-page":"275","article-title":"Prognostic Impact of TET2 Mutations in Patients with Acute Myeloid Leukemia: HM-SCREEN-Japan 01 and 02 Study","volume":"104","author":"Iyama","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1182\/blood-2023-180100","article-title":"Clinical Characteristics and Outcomes of Myeloid Neoplasms with MECOM Rearrangement: Results from a Nationwide Multicenter Study","volume":"142","author":"Chantana","year":"2023","journal-title":"Blood"},{"key":"ref_72","first-page":"109","article-title":"MECOM: A Very Interesting Gene Involved Also in Lymphoid Malignancies","volume":"45","author":"Liu","year":"2019","journal-title":"J. Assoc. Genet. Technol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2012.262","article-title":"ASXL1 Exon 12 Mutations Are Frequent in AML with Intermediate Risk Karyotype and Are Independently Associated with an Adverse Outcome","volume":"27","author":"Schnittger","year":"2012","journal-title":"Leukemia"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression","volume":"22","author":"Adli","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e6871","DOI":"10.1002\/cam4.6871","article-title":"Prognosis and Risk Factors for ASXL1 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome","volume":"13","author":"Yang","year":"2024","journal-title":"Cancer Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1111\/ajco.13897","article-title":"Prognostic Value of ASXL1 Mutations in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Meta-Analysis","volume":"19","author":"Zhang","year":"2023","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant P53 in Cancer: From Molecular Mechanism to Therapeutic Modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Nong, T., Mehra, S., and Taylor, J. (2024). Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies. Cells, 13.","DOI":"10.3390\/cells13161392"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Shin, D.-Y. (2023). TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited. Cancers, 15.","DOI":"10.3390\/cancers15194816"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-Mutant Acute Myeloid Leukemia with Decitabine and Venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular Characterization of Mutant TP53 Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3324\/haematol.2018.205013","article-title":"Clinical Implications of Subclonal TP53 Mutations in Acute Myeloid Leukemia","volume":"104","author":"Prochazka","year":"2018","journal-title":"Haematologica"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.exphem.2020.06.003","article-title":"AML Chemoresistance: The Role of Mutant TP53 Subclonal Expansion and Therapy Strategy","volume":"87","author":"Yan","year":"2020","journal-title":"Exp. Hematol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Su, L., Shi, Y.-Y., Liu, Z.-Y., and Gao, S.-J. (2022). Acute Myeloid Leukemia with CEBPA Mutations: Current Progress and Future Directions. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.806137"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41375-024-02140-x","article-title":"Prognostic Impact of CEBPA Mutational Subgroups in Adult AML","volume":"38","author":"Georgi","year":"2024","journal-title":"Leukemia"},{"key":"ref_86","unstructured":"Tian, T.V., and Graf, T. (2025, May 15). CEBPA (CCAAT\/Enhancer Binding Protein (C\/EBP), Alpha). Available online: https:\/\/atlasgeneticsoncology.org\/gene\/40050\/cebpa-%28ccaat-enhancer-binding-protein-%28c-ebp%29-alpha%29."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/bloodadvances.2021004292","article-title":"Prognostic Impact of CEBPA bZIP Domain Mutation in Acute Myeloid Leukemia","volume":"6","author":"Wakita","year":"2022","journal-title":"Blood Adv."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjh.17185","article-title":"How We Use Molecular Minimal Residual Disease (MRD) Testing in Acute Myeloid Leukaemia (AML)","volume":"193","author":"Dillon","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/bloodadvances.2024013214","article-title":"Measurable Residual Disease as Predictor of Post-Day +100 Relapses Following Allografting in Adult AML","volume":"9","author":"Ali","year":"2024","journal-title":"Blood Adv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-021-01148-5","article-title":"Prognostic and Therapeutic Implications of Measurable Residual Disease in Acute Myeloid Leukemia","volume":"14","author":"Aitken","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2012-07-444851","article-title":"Sense and Nonsense of High-Dose Cytarabine for Acute Myeloid Leukemia","volume":"121","year":"2013","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Zawacka, J.E. (2024). P53 Biology and Reactivation for Improved Therapy in MDS and AML. Biomark. Res., 12.","DOI":"10.1186\/s40364-024-00579-9"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-023-00954-z","article-title":"Time Independent Factors That Predict Relapse in Adults with Acute Myeloid Leukemia","volume":"14","author":"Lim","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/MOH.0000000000000626","article-title":"Genetic Heterogeneity and Clonal Evolution in Acute Myeloid Leukemia","volume":"28","author":"Meyer","year":"2021","journal-title":"Curr. Opin. Hematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e438662","DOI":"10.1200\/EDBK_438662","article-title":"Advancements and Challenges in the Treatment of AML","volume":"44","author":"Abaza","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/hematology.2020000089","article-title":"Management of Toxicities Associated with Targeted Therapies for Acute Myeloid Leukemia: When to Push through and When to Stop","volume":"2020","author":"Wang","year":"2020","journal-title":"Hematology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib Induces Deep Durable Remissions in Patients with Newly Diagnosed IDH1-Mutant Acute Myeloid Leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin Added to Chemotherapy and Continued Single-Agent Maintenance Therapy in Acute Myeloid Leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB Study of the FLT3 Kinase Inhibitor Midostaurin with Chemotherapy in Younger Newly Diagnosed Adult Patients with Acute Myeloid Leukemia","volume":"26","author":"Stone","year":"2012","journal-title":"Leukemia"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1158\/1078-0432.CCR-20-4271","article-title":"FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation","volume":"27","author":"Pulte","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1158\/2643-3230.BCD-24-0342","article-title":"Single-Cell Transcriptional Atlas of Human Hematopoiesis Reveals Genetic and Hierarchy-Based Determinants of Aberrant AML Differentiation","volume":"6","author":"Zeng","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Wu, X., Yang, X., Dai, Y., Zhao, Z., Zhu, J., Guo, H., and Yang, R. (2024). Single-Cell Sequencing to Multi-Omics: Technologies and Applications. Biomark. Res., 12.","DOI":"10.1186\/s40364-024-00643-4"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1038\/s41467-025-60333-z","article-title":"ScMODAL: A General Deep Learning Framework for Comprehensive Single-Cell Multi-Omics Data Alignment with Feature Links","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Jeong, Y., Ronen, J., Kopp, W., Lutsik, P., and Akalin, A. (2024). ScMaui: A Widely Applicable Deep Learning Framework for Single-Cell Multiomics Integration in the Presence of Batch Effects and Missing Data. BMC Bioinform., 25.","DOI":"10.1186\/s12859-024-05880-w"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Ma, L., Liu, J., Sun, W., Zhao, C., and Yu, L. (2025). ScMFG: A Single-Cell Multi-Omics Integration Method Based on Feature Grouping. BMC Genom., 26.","DOI":"10.1186\/s12864-025-11319-0"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Huang, J., Zhang, Z., Shen, H., Tang, X., Wu, D., Bao, X., Xu, G., and Chen, S. (2024). Application of Omics in the Diagnosis, Prognosis, and Treatment of Acute Myeloid Leukemia. Biomark. Res., 12.","DOI":"10.1186\/s40364-024-00600-1"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2024-204226","article-title":"Deconvolving Immunologic Networks of the AML Marrow Microenvironment with Spatial Multi-Omic Profiling","volume":"144","author":"Maurer","year":"2024","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1016\/j.cell.2024.04.013","article-title":"Mapping the Cellular Biogeography of Human Bone Marrow Niches Using Single-Cell Transcriptomics and Proteomic Imaging","volume":"187","author":"Bandyopadhyay","year":"2024","journal-title":"Cell"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1016\/j.cell.2022.05.013","article-title":"Mapping Information-Rich Genotype-Phenotype Landscapes with Genome-Scale Perturb-Seq","volume":"185","author":"Replogle","year":"2022","journal-title":"Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1158\/1538-7445.AM2025-3252","article-title":"Abstract 3252: Circulating Tumor DNA (CtDNA) Enables Enhanced Measurable Residual Disease (MRD) Detection and Non-Invasive Clonal Profiling in Acute Myeloid Leukemia (AML)","volume":"85","author":"Gunaratne","year":"2025","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Ili\u00e9, M., Hofman, V., Bontoux, C., Heeke, S., Lespinet-Fabre, V., Bordone, O., Lassalle, S., Lalv\u00e9e, S., Tanga, V., and Allegra, M. (2022). Setting up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France). Cancers, 14.","DOI":"10.3390\/cancers14092258"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Wang, Y., Yang, X., Liu, Y., and Li, Y. (2025). A Review of Common Immunotherapy and Nano Immunotherapy for Acute Myeloid Leukemia. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1505247"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1182\/blood.2021010721","article-title":"Phase 1\/2 Study of Uproleselan Added to Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia","volume":"139","author":"DeAngelo","year":"2022","journal-title":"Blood"},{"key":"ref_116","unstructured":"World Health Organization (2025). Advancing Equity and Resilience in a Turbulent World a Global Health Strategy for 2025\u20132028 Fourteenth General Programme of Work, World Health Organization."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Lee, H., Han, J.H., Kim, J.K., Yoo, J., Yoon, J.-H., Cho, B.S., Kim, H.-J., Lim, J., Jekarl, D.W., and Kim, Y. (2023). Machine Learning Predicts 30-Day Outcome among Acute Myeloid Leukemia Patients: A Single-Center, Retrospective, Cohort Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12185940"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"382","DOI":"10.25122\/jml-2019-0090","article-title":"Deep Learning for Acute Myeloid Leukemia Diagnosis","volume":"13","author":"Nazari","year":"2020","journal-title":"J. Med. Life"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/19\/2537\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:50:41Z","timestamp":1760035841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/19\/2537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":118,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["diagnostics15192537"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15192537","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]}}}